Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Felodipine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Felodipine. Displaying page 1 of 1.
    EudraCT Number: 2005-003976-39 Sponsor Protocol Number: CVAA489ADE01 Start Date*: 2005-11-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately respo...
    Medical condition: Patients with essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    M15 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001484-39 Sponsor Protocol Number: CVAA489ADE03 Start Date*: 2006-07-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the combination of valsartan 160 mg plus amlodipine 5 mg in hypertensive patients not adequately ...
    Medical condition: moderate essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    M15 10015488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004979-37 Sponsor Protocol Number: 06-004 Start Date*: 2006-10-27
    Sponsor Name:MediQuest Therapeutics, Inc.
    Full Title: Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon
    Medical condition: Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001078-34 Sponsor Protocol Number: 07-09-04/07 Start Date*: 2008-09-29
    Sponsor Name:Maastro Clinic
    Full Title: Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide
    Medical condition: Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000745-40 Sponsor Protocol Number: MEIN/20/ZoAm-Hyp/001 Start Date*: 2022-01-03
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA
    Full Title: Interventional clinical trial to assess efficacy and safety of the extemporaneous combination of Zofenopril calcium and amlodipine in grade 1-2 hypertensive patients versus each monotherapy
    Medical condition: Grade 1-2 hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004496-40 Sponsor Protocol Number: I5V-MC-TGAB Start Date*: 2013-03-01
    Sponsor Name:Eli Lilly and Company
    Full Title: Study of the Safety and Efficacy of LY3016859 after Multiple Intravenous Dosing in Diabetic Nephropathy Patients
    Medical condition: Chronic kidney disease associated with Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 100000004857 10012678 Diabetic nephropathy NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 02 20:13:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA